ADVANCED CANCER

This study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.

This study tested whether giving the drug lenvatinib before surgery helps remove advanced thyroid cancer more completely. 29 adults with invasive thyroid cancer took lenvatinib for a short time before their operation. The goal was to see if more patients could have clear or nearl…

This early-phase trial tested an experimental drug called NEV801 in 78 adults with advanced solid tumors that had stopped responding to standard treatments. The drug was given by IV in increasing doses to find the safest dose and to see if it had any anti-cancer effects. The stud…

This early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…

This study tested whether adding the drug axitinib to standard sandostatin LAR therapy could slow tumor growth in 256 people with advanced neuroendocrine tumors (G1-G2) that started outside the pancreas. Participants received either the combination or sandostatin plus a placebo. …

This phase 2 trial tested whether combining two immunotherapy drugs, nivolumab and relatlimab, can help people with advanced or metastatic soft-tissue sarcoma. The study enrolled 68 adults whose tumors had a specific immune structure. Researchers measured how many patients had th…

This early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond bett…

This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). …

This early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…

This early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…

This early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …

This study tested a combination of two drugs, lenvatinib and eribulin, in 30 people with advanced soft tissue sarcomas (liposarcoma or leiomyosarcoma) that could not be removed by surgery or had spread. The goal was to see if the combo could shrink tumors or slow their growth. Th…

This early-phase study tested adding the drug pirfenidone to standard chemotherapy for people with advanced non-small cell lung cancer. The main goals were to find a safe dose and see if the combination could shrink tumors. 48 participants were enrolled, and the study is now comp…

This early-phase trial tested several combinations of cancer drugs, including niraparib, TSR-042, bevacizumab, and various chemotherapies, in 60 patients with advanced or metastatic cancer. The main goal was to find safe doses for future studies. The trial has been completed, but…

This study tested whether the immunotherapy drug nivolumab can help prevent esophageal cancer from coming back after surgery. About 794 people who had surgery for stage II or III cancer of the esophagus or gastroesophageal junction received either nivolumab or a placebo. The main…

This study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…

This early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…

This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five day…

This study tested whether putting special elastic tape on the belly can help relieve severe pain, bloating, and nausea in people with advanced cancer who have bowel blockage and fluid buildup. 38 adults whose symptoms didn't improve after standard treatments were randomly assigne…

This study tested whether a one-week physiotherapy program could improve movement, walking, and daily independence in 32 advanced cancer patients receiving palliative care. The program included exercises, mobility training, and breathing therapy tailored to each patient. Research…

This study tested whether asking cancer patients to complete a symptom questionnaire online before their doctor visit could help identify who might benefit from a palliative care referral. Forty adults with advanced cancer participated. The goal was to see if this approach is pra…

This study tested a program that teaches couples communication skills when one partner has advanced cancer. About 440 patients and their partners took part, with half receiving the training and half getting general healthy living information. The goal was to see if the training c…

This study tested a mobile app called STAMP+CBT for advanced cancer patients with chronic pain. The app helps patients track their pain, mood, and opioid use while providing tailored education and cognitive behavioral therapy (CBT) exercises. Fifty-two patients used the app for 4…

This study tested a new program called SMILE that helps teens and young adults (ages 15-29) with advanced cancer manage symptoms like pain, fatigue, and emotional distress. The program includes four video sessions at home, teaching relaxation and coping skills. Researchers checke…

This study tested a program called CONTINUUM, where advanced cancer patients had a video visit with an oncology nurse within three days of leaving the hospital. The goal was to help patients feel more confident managing their health and improve communication with their care team.…

This study looked at how patients with advanced cancer respond to being offered a conversation about their future care preferences. Researchers invited 71 patients to discuss their wishes and tracked who took part. The goal was to learn more about what helps patients feel ready t…

This study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…

This study tested a website designed to help people with advanced cancer and their family caregivers talk about advance care planning. Researchers worked with 36 patient-caregiver pairs to see if the website was easy to use and helpful. The main goal was to gather feedback to imp…

This completed study reviewed medical records of 1,250 advanced cancer patients who visited the emergency department. Researchers looked at factors like age, tumor type, and blood test results to see which patients were at higher risk of dying within 90 days. The goal is to help …